Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (6105)	4/8/2002 12:00:07 PM
From: Jibacoa	Read Replies (1) \| Respond to of 52153

<<Sorry about the formatting.>> Peter: I don't know if this one helps, but I was able to read it better.<g> By the way, they are projecting a $72 price for ITMN.<g> biz.yahoo.com RAGL Bernard. The Leerink Swan report on ITMN Source: Leerink Swann & Company estimates, Bloomberg Stck Prce Shrs Out. Mrkt Net Tech. Revn[3]FY:03ERev. Mltpl Ticker 4/4/02 (thousands)[1] Value Cash [1]Value[2]FY:02E FY:03E Mkt. Val. Tech. Val. IMMU $17.96 49,691 $892.5 $47.5 $844.9 $14.7 $24.2 36.9 x 34.9 x ICOS $43.52 59,967 $2,609 $466.9 $2,142.9 $87.8 $66.6 39.2 x 32.2 x OSIP $35.74 36,159 $1,292 $398.7 $893.6 $22.1 $33.6 38.5 x 26.6 x REGN $22.40 43,964 $984.8 $237.8 $747.0 $20.8 $31.4 31.4 x 23.8 x IMCL $22.96 73,334 $1,683 $91.4 $1,592.4 $30.9 $70.4 23.9 x 22.6 x CERS $56.64 15,754 $892.3 $118.4 $774.0 $10.2 $37.0 24.1 x 20.9 x ALXN $21.40 18,128 $387.9 $217.0 $170.9 $9.5 $10.0 38.8 x 17.1 x CBST $18.02 28,299 $509.9 $30.7 $479.2 $15.5 $28.8 17.7 x 16.7 x TRMS $41.23 18,699 $771.0 $113.9 $657.1 $3.8 $47.4 16.3 x 13.9 x CVTX $33.81 23,290 $787.4 $277.5 $509.9 $5.0 $58.2 13.5 x 8.8 x TKTX $40.07 34,342 $1,376 $399.8 $976.3 $46.1 $119.6 11.5 x 8.2 x Average: $1,108.0 $889.8 26.5 x 20.5 x ITMN $30.02 31,504 $945.7 $287.7 $658.0 $99.7 $183.3 5.2 x 3.6 x Discount: 81% 82% [1] As of 12/31/01. Data for Alexion Pharmaceuticals as of 1/31/02. Data for ImClone as of 09/30/01. Adjusted for subsequent financings. [2] Market value less net cash. [3] I/B/E/S estimates, except for Transkaryotic Therapies, which are Leerink Swann & Company estimates.